Alnylam Pharmaceuticals PT Raised to $80.00 (ALNY)
Investment analysts at Deutsche Bank lifted their target price on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) to $80.00 in a note issued to investors on Tuesday, AnalystRatingsNetwork reports. Deutsche Bank’s price objective would indicate a potential upside of 26.88% from the company’s current price.
ALNY has been the subject of a number of other recent research reports. Analysts at Needham & Company upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) to a “positive” rating in a research note to investors on Monday. They now have a $65.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) to $80.00 in a research note to investors on Monday. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note to investors on Friday, August 16th. They now have a $51.00 price target on the stock.
Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $61.75.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 63.05 on Tuesday. Alnylam Pharmaceuticals has a 1-year low of $14.88 and a 1-year high of $63.84. The stock has a 50-day moving average of $52.39 and a 200-day moving average of $35.78. The company’s market cap is $3.970 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.06. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.99 million. During the same quarter in the prior year, the company posted ($0.25) earnings per share. The company’s quarterly revenue was down 58.4% on a year-over-year basis. Analysts expect that Alnylam Pharmaceuticals will post $-1.25 EPS for the current fiscal year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore unloaded 58,947 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $55.50, for a total value of $3,271,558.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.